About GW Pharma
GW Pharma is a Healthcare company based in Cambridge (United Kingdom) founded in 1998, and was acquired by Jazz Pharmaceuticals in February 2021. Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy. GW Pharma has raised $46.5 million across 3 funding rounds from investors including Jazz Pharmaceuticals and Mentor Capital. GW Pharma offers products and services including Xywav, Epidiolex, Defitelio, and Rylaze. Its focus areas include HealthTech, Cannabis HealthTech, Cannabinoid Therapeutics and Neurological Disorders. Its legal entity is GW PHARMA LIMITED.
Company details
GW Pharma was founded in 1998 in Cambridge, United Kingdom, within the pharmaceutical sector. Focus is placed on developing cannabinoid-based treatments, including Sativex for managing spasticity in multiple sclerosis patients and pain in cancer cases, as well as Epidiolex for addressing epilepsy in children. Operations center on research and drug approval processes across Europe and beyond, targeting neurological and pain-related conditions.
- Headquarters Cambridge, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website gwpharm.com
- Social LinkedIn YouTube
- Acquired by Jazz Pharmaceuticals (Feb 2021)
- Legal Name Gw Pharma Limited
- Date of Incorporation 29 Jan, 1999
- Jurisdiction CAMBRIDGE
- Total Equity Funding$46.5M (USD)
in 3 rounds
- Latest Funding Round$1M (USD), Post-IPO
Mar 2017
- InvestorsJazz Pharmaceuticals
& 1 more
- Acquired byJazz Pharmaceuticals
(Feb 2021)
Products & Services of GW Pharma
GW Pharma offers a comprehensive portfolio of products and services, including Xywav, Epidiolex, Defitelio, and Rylaze.
Oral solution for treating narcolepsy and idiopathic hypersomnia
Cannabidiol-based treatment for epilepsy seizures
Therapy for preventing complications in leukemia patients
Recombinant treatment for acute lymphoblastic leukemia
Apps and channels of GW Pharma
its YouTube channel Jazz Pharmaceuticals has 93 subscribers and 24 videos.
Videos from GW Pharma
The most watched videos on GW Pharma's YouTube channel, Jazz Pharmaceuticals (93 subscribers). Click a video to play it here.
More on Jazz Pharmaceuticals.
Funding Insights of GW Pharma
GW Pharma has successfully raised a total of $46.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $46.5M
- Total Rounds 3
- Last Round Post-IPO — $1M
- First Round $31.5M
(Jun 2003)
- Investors Count 1
All 3 funding rounds of GW Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2017 | $1M | Post-IPO | – | – | |
| Jan 2006 | $15M | Series C | – | – | – |
| Jun 2003 | $31.5M | Series C | – | – | – |
2 investors in total: 2 institutional.
Investors in GW Pharma
GW Pharma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Jazz Pharmaceuticals and Mentor Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Energy investments and funding for pre-IPO companies in oil, gas, coal, and uranium sectors. | mentorcapital.com | |||
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | jazzpharma.com | Dublin, Ireland |
Investor details for GW Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GW Pharma
792 people are tracked at GW Pharma (422 in leadership, 13 in board & advisors, 357 in team).
| Name | Role | Group |
|---|---|---|
Matt Lasmanis | Chief Digital Officer (cdo) | Leadership |
Patricia Carr | Senior Vice President, Chief Accounting Officer | Leadership |
Ngozi Nina K. | Global Strategic Market Insights, Director | Leadership |
Kenneth Low | Director, Omnichannel Strategic Partner | Leadership |
Ramya Nair | Director Global Strategic Market Insights | Leadership |
Anthony O. | Director, Global Strategic Market Insights | Leadership |
Heidi Manna | EVP & Chief People Officer | Leadership |
Robert Iannone | EVP, R&D & Chief Medical Offer | Leadership |
Yajun Liu | Director Of Clinical Pharmacology | Leadership |
Joshua Allen | Chief Scientific Officer, Oncology | Leadership |
Matt Kosior | Director, Corporate And Securities Counsel | Leadership |
Tej Grewal | Director, Talent Solutions | Leadership |
Sonia Hardaway | Head Of Organizational And Talent Solutions | Leadership |
Jessica Sacks | Associate Medical Director, Sleep | Leadership |
Joanne | Executive Director And Clinical Pharmacology Oncology TA Head | Leadership |
Kedar Vaidya | Associate Director - Pharmacology, Early Development (oncology) | Leadership |
Ju Shi | Associate Director, Pharmacology | Leadership |
Stefanie Bronson | Director, Medical Communications | Leadership |
Purvi Dev | Senior Director, Commercial Forecasting And Analytics | Leadership |
Dennis Salotti | Executive Director & Head, Clinical Outsourcing & Innovation | Leadership |
772 more people are available in the full profile.
Complete people profiles for GW Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GW Pharma
5 dated milestones of GW Pharma across 23 years, from founding to its latest funding, stage changes and deals.
- Founded GW Pharma is founded.
- Funding First funding round of $31.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $1.0M.
- Exit Acquired by Jazz Pharmaceuticals.
Web traffic of GW Pharma
Websites that share an audience with GW Pharma (gwpharm.com).
Websites whose visitors overlap most with GW Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ligand.com | 100% | 7K | #3,254,882 | View details | |
| astellas.com | 73% | 170.7K | #288,207 | View details | |
| thresholdpharm.com | 73% | View details | |||
| mylan.com | 73% | 26.4K | #1,585,141 | View details | |
| arenapharm.com | 72% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for GW Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gw Pharma
Complete news archive for GW Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GW Pharma
GW Pharma was founded in 1998 and raised its 1st funding round 5 years after it was founded.
GW Pharma is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
GW Pharma is a funded company, having raised a total of $46.5M across 3 funding rounds to date. The company's 1st funding round was a Series C of $31.5M, raised on Jun 2003.
GW Pharma was founded in 1998 in Cambridge, United Kingdom, within the pharmaceutical sector. Focus is placed on developing cannabinoid-based treatments, including Sativex for managing spasticity in multiple sclerosis patients and pain in cancer cases, as well as Epidiolex for addressing epilepsy in children. Operations center on research and drug approval processes across Europe and beyond, targeting neurological and pain-related conditions.
GW Pharma offers Xywav, Epidiolex, Defitelio, and Rylaze.
GW Pharma has 2 investors. Key investors include Jazz Pharmaceuticals, and Mentor Capital.
GW Pharma operates through Gw Pharma Limited.
Yes. GW Pharma was acquired by Jazz Pharmaceuticals in February 2021.